Evolocumab reduces MACE by 29% in patients with BMI greater than or equal to 35 kg/mEvolocumab shows greater heart protection for patients with higher BMI

This randomized controlled trial evaluated the efficacy and safety of evolocumab in 27,564 patients with stable atherosclerotic cardiovascular disease. The study was designed as a prespecified analysis to determine if patient body mass index (BMI) influenced the treatment effect of evolocumab on major adverse cardiovascular events (MACE). MACE was defined as cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

The intervention group received evolocumab, while the control group received a placebo. The median follow-up period for the study was 2.2 years. Researchers analyzed the primary outcome across different BMI strata to identify potential interactions between patient weight and treatment efficacy.

Primary outcome results showed significant risk reductions for all BMI categories. In patients with a BMI <30 kg/m, evolocumab resulted in an 11% reduction in MACE (HR: 0.89; 95% CI: 0.81-0.98). For patients with a BMI between 30 and <35 kg/m, the relative risk reduction was 14% (HR: 0.86; 95% CI: 0.75-0.98). The most substantial relative risk reduction was observed in patients with a BMI ≥35 kg/m, who experienced a 29% reduction in MACE (HR: 0.71; 95% CI: 0.59-0.86).

Absolute risk reductions were also reported across the groups. Patients with a BMI <30 kg/m saw an absolute risk reduction of 1.4%. Those with a BMI between 30 and <35 kg/m had an absolute risk reduction of 1.8%. The largest absolute risk reduction was observed in the highest BMI category (≥35 kg/m), which recorded a 5.7% reduction. A statistically significant interaction between BMI and treatment arm for primary endpoint reduction was observed (P for interaction = 0.025), indicating that the relative risk reduction increased progressively with higher BMI categories.

In terms of baseline risks, the study noted that in the placebo arm, every 5-unit increase in BMI above 30 kg/m was associated with an 11% higher risk of the primary endpoint (HR: 1.11; 95% CI: 1.02-1.21).

Safety and tolerability data, including specific adverse event rates or discontinuation rates, were not reported in the provided data. However, the study design as a randomized controlled trial allows for a direct association between evolocumab treatment and the observed reduction in MACE.

These results provide evidence that while evolocumab is effective across all BMI levels, the relative magnitude of benefit increases significantly in patients with higher body mass indices. This finding is clinically relevant because it suggests that the impact of PCSK9 inhibition may be more pronounced in patients with obesity or high BMI, who often present with a higher baseline risk for cardiovascular events.\n Methodological limitations include the lack of reported safety data and specific details regarding the study setting. While the P-value for interaction (0.025) supports the trend of increasing benefit with higher BMI, it is important to note that absolute risk reductions remain relatively small across all groups (ranging from 1.4% to 5.7%).

Clinical implications suggest that clinicians may find evolocumab particularly impactful for patients with a BMI ≥35 kg/m due to the 29% relative risk reduction. However, practitioners should consider both absolute and relative risks when making treatment decisions. Questions remain regarding the long-term safety profile and how these results translate into specific clinical guidelines for overweight versus obese populations.